Comparative Study of Fluoxetine, Acamprosate, and Their Combination in patients with co-occurring Depression and Alcohol Dependence: A Randomized Controlled Trial - NIL

Start Date01 Sep 2026

Sponsor / Collaborator-

NCT07204977

/ RecruitingPhase 1IIT

Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)

Background:
Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time. Half of all people with ALS live only 3 to 5 years after diagnosis. Current drug treatments can slow the progress of the disease, but they cannot stop or reverse it.
Objective:
To test a study drug (acamprosate) in people with ALS with a mutation in the C9orf72 gene.
Eligibility:
People aged 18 years and older with ALS. They must have a mutation in the C9orf72 gene.
Design:
Participants will have 13 visits over 32 weeks. Five visits will be at the clinic, and 8 visits will be by phone.
Participants will have a baseline visit of up to 3 days. They will have a physical exam with blood tests. They will have imaging scans and tests of their breathing ability. Their memory, thinking, and behavior will be assessed. They will have a neurologic exam to check their reflexes, strength, balance, eyes, and coordination. They will complete questionnaires about their daily life. They will have a lumbar puncture to collect fluid from the area around the spinal cord.
Acamprosate is a pill taken by mouth. Participants will take 2 pills by mouth 3 times a day with meals for 24 weeks. They will record their doses and any missed doses in a diary.
Baseline tests will be repeated during follow-up clinic visits. These tests may be spread out over 3 days.
During phone visits, participants will talk about how they are doing. They will review their diary with researchers.

Start Date02 Feb 2026

Sponsor / Collaborator

National Institute of Neurological Disorders & Stroke

100 Clinical Results associated with Acamprosate Calcium

100 Translational Medicine associated with Acamprosate Calcium

100 Patents (Medical) associated with Acamprosate Calcium

967

Literatures (Medical) associated with Acamprosate Calcium

01 Nov 2026·DRUG AND ALCOHOL DEPENDENCE

Nationwide trends of six medications for alcohol use disorder prescriptions post-discharge in patients hospitalized with alcohol-associated liver disease between 2015 and 2024

Article

Author: Yeo, Yee Hui ; Zhang, Wei ; Ting, Peng-Sheng ; Yang, Hsien Yao ; Chan, Shu-Yen

INTRODUCTION:

Alcohol associated liver disease (ALD) carries a high risk of hospitalization and recidivism, yet post-discharge medications for alcohol use disorder (MAUD) are not universally prescribed. MAUD prescriptions have been associated with reduced recidivism and hepatic decompensation. However, national data on prescribing patterns is limited. We examined ten-year trends in six MAUD prescriptions after hospitalization for ALD.

METHODS:

We identified 150,241 US adults hospitalized with ALD between 2015 and 2024 using electronic health records from TriNetX. Outcomes included annual prevalence, incidence rate, and incidence proportion of post-discharge MAUD prescriptions. FDA-approved agents included disulfiram, acamprosate, and naltrexone; off-label agents included topiramate, baclofen, and gabapentin. Trends were assessed using Joinpoint regression with annual percentage change (APC) and average annual percentage change (AAPC). Subgroup analyses were stratified by cirrhosis status and sex.

RESULTS:

FDA-approved MAUD had consistently lower prescription rates than off-label agents over the past decade. From 2015-2024, disulfiram was the only FDA-approved agent with a declining trend, while acamprosate (AAPC 20.35%) and naltrexone (AAPC 17.83%) demonstrated significant increases for new prescriptions. By 2024, the prevalence of FDA-approved and off-label MAUD prescriptions were 17.98% and 41.96%, respectively. Patients with cirrhosis had lower prescribing rates but exhibited greater relative increases in FDA-approved MAUD prescriptions. Women were more likely to receive off-label prescriptions, though both sexes showed similar upward trends.

CONCLUSION:

Post-discharge MAUD prescribing for ALD has risen significantly, but less than 20% of patients receive FDA-approved MAUD. Expanding access to evidence-based medications is critical to improve outcomes in this high-risk population.

01 Oct 2026·Journal of Obstetrics and Gynaecology Canada

SOGC Clinical Practice Guideline No. 471: Alcohol and Pregnancy

Review

Author: Christie, Janet ; Allen, Victoria ; Thompson, Heather ; Cook, Jocelynn L ; Chandrasekaran, Nirmala ; Ouellet, Annie

OBJECTIVE:

To establish national standards of care for screening and counselling pregnant women and individuals of reproductive age regarding alcohol consumption and alcohol use disorder.

INTENDED USERS:

Health care providers who care for pregnant women and women of childbearing age.

TARGET POPULATION:

Pregnant women and women of childbearing age and their families.

EVIDENCE:

Medline, EMBASE, and CENTRAL databases were searched for "alcohol use and pregnancy". The results were filtered for a publication date between October 2018 and February 2026. The search terms were developed using the MeSH terms and key words including: pre-pregnancy, pregnant, breast feeding, lactation, female, women, preconception care, prenatal care, Fetal Alcohol Spectrum Disorder, prenatal alcohol exposure, drinking behavior, alcohol abstinence, alcohol drinking, binge drinking, Alcohol-Related Disorders, alcoholism, alcohol consumption, alcohol abuse, benzodiazepines, disulfiram, naltrexone, acamprosate, ondansetron, topiramate, cyanamide, calcium carbimide, alcohol deterrents, disease management, detoxification, Alcoholics Anonymous, alcohol counselling, harm reduction, pre-pregnancy care, prenatal care, incidence, prevalence, epidemiological monitoring, brief intervention. Clinical trials, observational studies, reviews, systematic reviews and meta-analysis, guidelines, and conference consensus were included. The table of evidence from the search that supports the recommendations is included as Appendix B.

VALIDATION METHODS:

The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and conditional recommendations).

BENEFITS, HARMS, AND COSTS:

Implementation of the recommendations in these guidelines may increase obstetrical care provider recognition of alcohol consumption and problematic alcohol use among women of childbearing age or who are pregnant using validated screening tools and brief intervention approaches. Obstetrician-gynecologists should be given priority access to healthcare professionals with expertise in alcohol cessation for their patients in order to support optimal health and pregnancy outcomes. As they are already responsible for the urgent management of pregnancy-related complications, they must be able to rely on expedited referral pathways to ensure timely interventions.

SUMMARY STATEMENTS:

RECOMMENDATIONS: (Recommendations IN BOLD are new to this guideline update; an overview of the updated supporting literature for all recommendations is provided in Appendix B).

20 Sep 2026·ALCOHOL AND ALCOHOLISM

Pharmacological interventions for alcohol use disorder on quality of life: a meta-analysis of randomized controlled trials

Review

Author: Kim, Paul ; Fluyau, Dimy ; Revadigar, Neelambika

Abstract:

Aims:

Quality of life (QoL), a critical factor for sustaining recovery from alcohol use disorder (AUD), has been examined as an AUD-related outcome in randomized controlled trials (RCTs) that evaluated pharmacotherapy for AUD. This review evaluates the efficacy of this therapy in improving mental and physical health-related QoL.

Methods:

RCTs were identified across seven databases. Study quality was evaluated using the Cochrane risk-of-bias tool for randomized trials version 2. A systematic review with meta-analysis was conducted. The review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and was registered with PROSPERO (CRD420261277890).

Results:

Eighteen RCTs with 4376 participants were evaluated. Naltrexone was linked to improvements in both mental QoL (d = 0.30, 95% CI: 0.08–0.52) and physical QoL (d = 0.16, 95% CI: 0.01–0.31). Nalmefene improved physical QoL (d = 0.13, 95% CI: 0.02–0.25) but not mental QoL (d = 0.18, 95% CI: −0.004 to 0.354). Topiramate showed no improvement in either domain. However, further analysis indicated that topiramate was associated with a small improvement in physical QoL, which could correlate with a reduced percentage of heavy drinking days. Interpret these findings with caution. Acamprosate, sertraline, and psilocybin were associated with improved mental or physical QoL, whereas ketamine, varenicline, levetiracetam XR, and quetiapine were not. Interpretation is limited to single trials—no eligible RCTs reporting the specified QoL outcomes for disulfiram.

Conclusions:

Certain medications for AUD are linked with improved mental and physical QoL, but evidence remains limited. Future RCTs should assess QoL and establish whether improvements are clinically meaningful.

News (Medical) associated with Acamprosate Calcium

05 Oct 2026

·www.prnewswire.com

SereNeuro Therapeutics Closes Oversubscribed Pre-Seed Financing to Advance Non-Opioid Pain Pipeline

Lead program SN101, a first-in-class non-opioid iPSC-derived therapy for chronic joint pain, moves toward IND-enabling studies BALTIMORE and PHOENIX, Oct. 5, 2026 /PRNewswire/ -- SereNeuro Therapeutics, a preclinical-stage biotechnology company developing non-opioid therapies for pain, today announced the close of its oversubscribed pre-seed financing. The round advances the company's lead program, SN101, toward Investigational New Drug (IND)-enabling activities and supports its second program, SN102. Continue Reading SereNeuro Therapeutics founding team (left to right): Zhuolun (Poppy) Wang, Ph.D., co-founder; Tea Soon Park, Ph.D., Head of Cell Therapy; Xinzhong Dong, Ph.D., co-founder; Gabsang Lee, D.V.M., Ph.D., co-founder; and Daniel Saragnese, MBA, CEO and co-founder. Photo courtesy of SereNeuro Therapeutics. The syndicate included two Maryland-based venture firms and a physician investor. Qualifying investors structured their investments through Maryland's Biotechnology Investment Incentive Tax Credit at the enhanced refundable rate available to companies located in a federal Opportunity Zone, which includes SereNeuro's East Baltimore site. "Non-opioid pain therapeutics have become one of the most active corners of biotech this year, with an IPO, nine-figure financings, and pharma licensing deals, nearly all of it chasing one family of sodium channels for symptom relief," said Daniel Saragnese, MBA, CEO and co-founder of SereNeuro Therapeutics. "SereNeuro brings a different biology to the same problem. SN101 is made of living human sensory neurons that carry the full pain-channel identity of a native human dorsal root ganglion, or DRG, neuron: Nav1.7, Nav1.8, and Nav1.9, which most stem-cell-derived neurons lack. SN101 cells are designed to relieve pain and preserve the joint. This capital, with the non-dilutive funding we continue to secure, carries SN101 toward the manufacturing and preclinical studies an IND requires." SN101 is an off-the-shelf, non-opioid therapy made of purified human pain-sensing neurons derived from induced pluripotent stem cells (iPSCs). Delivered by a single injection into the affected joint, it is designed to relieve chronic joint pain while preserving joint structure, and it has demonstrated preclinical proof of concept. The technology was developed by co-founders Xinzhong Dong, Ph.D., Gabsang Lee, D.V.M., Ph.D., and Zhuolun (Poppy) Wang, Ph.D. "Gabsang and I began this collaboration to build a human iPSC-derived model of peripheral pain-sensing neurons, pure and specific enough to control for neuron subtype, so we could discover new non-opioid pain drug targets. It was never meant to be a drug. We were testing the cells' function to validate the model. A joint pain model was available, and when we put the cells into the joint, we saw a therapeutic effect we had not set out to find. That observation became SN101," said Xinzhong Dong, Ph.D., co-founder and scientific advisor. SN102, the company's second program, is a gene therapy for trigeminal neuralgia and other neuropathic pain. "Our goal with SN102 is a single treatment that turns down pain signaling in trigeminal neuralgia and other neuropathic pain, from the neurons themselves, without opioids and without numbing everything else," said Zhuolun (Poppy) Wang, Ph.D., co-founder and scientific advisor. In September 2026, after the financing closed, SereNeuro received its first NIH Small Business Innovation Research (SBIR) award, supporting SN102 through the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative, an NIH-wide effort to speed scientific solutions to the opioid crisis, including non-addictive treatments for pain. SereNeuro's pipeline is built for that purpose. The company was also selected by the Alliance for Regenerative Medicine to present an Innovation Spotlight at the 2026 Cell & Gene Meeting on the Mesa, taking place today: Date: Monday, October 5, 2026 Time: 2:30 p.m. MST (5:30 p.m. EDT) Location: Frank Lloyd Wright Ballroom G, Arizona Biltmore, Phoenix About SereNeuro Therapeutics SereNeuro Therapeutics is a preclinical-stage biotechnology company developing first-in-class non-opioid therapies for pain, including iPSC-derived neuron therapies and gene therapies, led by SN101. For more information, visit . SereNeuro's SN102 program is supported by the National Institute of Dental and Craniofacial Research of the National Institutes of Health under Award Number R43DE035747. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Media Contact Daniel Saragnese, MBA, CEO and co-founder [email protected] +1 410-205-9387 SOURCE SereNeuro Therapeutics, Inc. 21% more press release views with Request a Demo

Gene Therapy

05 Oct 2026

·www.biospace.com

SereNeuro Therapeutics Closes Oversubscribed Pre-Seed Financing to Advance Non-Opioid Pain Pipeline

Lead program SN101, a first-in-class non-opioid iPSC-derived therapy for chronic joint pain, moves toward IND-enabling studies BALTIMORE and PHOENIX , Oct. 5, 2026 /PRNewswire/ -- SereNeuro Therapeutics, a preclinical-stage biotechnology company developing non-opioid therapies for pain, today announced the close of its oversubscribed pre-seed financing. The round advances the company's lead program, SN101, toward Investigational New Drug (IND)-enabling activities and supports its second program, SN102. The syndicate included two Maryland-based venture firms and a physician investor. Qualifying investors structured their investments through Maryland's Biotechnology Investment Incentive Tax Credit at the enhanced refundable rate available to companies located in a federal Opportunity Zone, which includes SereNeuro's East Baltimore site. "Non-opioid pain therapeutics have become one of the most active corners of biotech this year, with an IPO, nine-figure financings, and pharma licensing deals, nearly all of it chasing one family of sodium channels for symptom relief," said Daniel Saragnese, MBA, CEO and co-founder of SereNeuro Therapeutics. "SereNeuro brings a different biology to the same problem. SN101 is made of living human sensory neurons that carry the full pain-channel identity of a native human dorsal root ganglion, or DRG, neuron: Nav1.7, Nav1.8, and Nav1.9, which most stem-cell-derived neurons lack. SN101 cells are designed to relieve pain and preserve the joint. This capital, with the non-dilutive funding we continue to secure, carries SN101 toward the manufacturing and preclinical studies an IND requires." SN101 is an off-the-shelf, non-opioid therapy made of purified human pain-sensing neurons derived from induced pluripotent stem cells (iPSCs). Delivered by a single injection into the affected joint, it is designed to relieve chronic joint pain while preserving joint structure, and it has demonstrated preclinical proof of concept. The technology was developed by co-founders Xinzhong Dong, Ph.D., Gabsang Lee, D.V.M., Ph.D., and Zhuolun (Poppy) Wang, Ph.D. "Gabsang and I began this collaboration to build a human iPSC-derived model of peripheral pain-sensing neurons, pure and specific enough to control for neuron subtype, so we could discover new non-opioid pain drug targets. It was never meant to be a drug. We were testing the cells' function to validate the model. A joint pain model was available, and when we put the cells into the joint, we saw a therapeutic effect we had not set out to find. That observation became SN101," said Xinzhong Dong, Ph.D., co-founder and scientific advisor. SN102, the company's second program, is a gene therapy for trigeminal neuralgia and other neuropathic pain. "Our goal with SN102 is a single treatment that turns down pain signaling in trigeminal neuralgia and other neuropathic pain, from the neurons themselves, without opioids and without numbing everything else," said Zhuolun (Poppy) Wang, Ph.D., co-founder and scientific advisor. In September 2026, after the financing closed, SereNeuro received its first NIH Small Business Innovation Research (SBIR) award, supporting SN102 through the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative, an NIH-wide effort to speed scientific solutions to the opioid crisis, including non-addictive treatments for pain. SereNeuro's pipeline is built for that purpose. The company was also selected by the Alliance for Regenerative Medicine to present an Innovation Spotlight at the 2026 Cell & Gene Meeting on the Mesa, taking place today: Date: Monday, October 5, 2026 Time: 2:30 p.m. MST (5:30 p.m. EDT) Location: Frank Lloyd Wright Ballroom G, Arizona Biltmore, Phoenix About SereNeuro Therapeutics SereNeuro Therapeutics is a preclinical-stage biotechnology company developing first-in-class non-opioid therapies for pain, including iPSC-derived neuron therapies and gene therapies, led by SN101. For more information, visit . SereNeuro's SN102 program is supported by the National Institute of Dental and Craniofacial Research of the National Institutes of Health under Award Number R43DE035747. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Media Contact Daniel Saragnese, MBA, CEO and co-founder info@sereneuro.com +1 410-205-9387 View original content to download multimedia: SOURCE SereNeuro Therapeutics, Inc.

27 May 2026

·www.einpresswire.com

Harmony Grove Connecting Clients With Medication-Assisted Treatment Providers in Houston, Texas

Harmony Grove blends evidence-based, and holistic outpatient treatment and community partnerships for MAT to create an environment focused on lasting recovery. HOUSTON, TX, UNITED STATES, May 27, 2026 / EINPresswire.com / -- Harmony Grove Behavioral Health in Houston emphasizes its partnership-based approach to medication-assisted treatment (MAT) , connecting clients with local MAT providers and medication management while delivering comprehensive outpatient services that integrate clinical care with a broader healing community. This coordinated model personalizes treatment plans and combines evidence-based therapies, holistic support, and family involvement to strengthen long-term recovery from opioid and alcohol use disorders. Harmony Grove does not operate MAT programs directly but partners with local Houston facilities to ensure clients have access to FDA-approved medications and professional medication management alongside outpatient services. This collaborative approach allows Harmony Grove to tailor each client’s program while integrating resources across the city, creating a culture of support that helps individuals fully engage in therapy and recovery. Medication-assisted treatment uses prescribed medications to target symptoms of addiction, support withdrawal management, reduce cravings, and create stability that enables meaningful participation in counseling and peer-based therapies. MAT is not a stand-alone solution; it functions as a complementary component of a holistic treatment plan that includes individual and group therapy, evidence-based modalities, and ongoing follow-up care. Managing withdrawal and cravings with medication can empower clients to better engage with CBT, DBT, motivational interviewing, EMDR, and relapse prevention work, improving retention in treatment and reducing the risk of overdose. Harmony Grove’s partnerships make a range of FDA-approved medications available, as appropriate for the individual client. Options include buprenorphine and Suboxone for outpatient opioid treatment, methadone for severe cases managed through specialized clinics, naltrexone for relapse prevention following detox, naloxone for overdose, and medications such as acamprosate and disulfiram for alcohol dependence. Clinicians work with clients to determine the most suitable medication strategy, recognizing that medication selection depends on clinical history, treatment goals, and the stage of recovery. Harmony Grove serves adults in Houston who struggle with opioid addiction, alcohol dependence, and co-occurring mental health disorders. The outpatient program emphasizes individualized treatment planning that accounts for trauma history, mental health conditions, and psychosocial needs. Medication-assisted treatment is integrated with individual counseling, group therapy, experiential interventions, and holistic support, including nutrition, movement, and mind-body practices. This whole-person approach helps clients address underlying drivers of substance use and develop life skills necessary for sustainable sobriety. As a dedicated outpatient facility, Harmony Grove offers in-person and flexible scheduling options for individuals balancing recovery with work, school, or family responsibilities. Outpatient care is designed to make treatment accessible without sacrificing intensive therapeutic support. MAT services provided through local partners are coordinated with Harmony Grove’s clinicians to ensure continuity of care and timely adjustments to medication management as recovery needs evolve. Family involvement and community are key elements to their program, as connection is essential to recovery. Family integration into intensive outpatient and aftercare programs provides education, communication strategies, and follow-up counseling that support both clients and loved ones. Peer and alumni support add community-based encouragement that reduces isolation and reinforces positive change. Harmony Grove combines MAT with evidence-based therapies, including cognitive-behavioral therapy, dialectical behavior therapy, motivational interviewing, and EMDR. The program seeks to improve treatment retention, reduce overdose risk, and support better behavioral health outcomes through a balanced mix of clinical rigor and compassionate community. For more information about how MAT may fit into your recovery plan or to discuss outpatient options, contact the admissions team at Harmony Grove today. Matt Handy Harmony Grove Behavioral Health +1 713-564-6468 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Acamprosate Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D02780	Acamprosate Calcium	N07BB03	DB00659

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alcoholism	United States	Forest Laboratories, Inc.	29 Jul 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Binge-Eating Disorder	Phase 3	United States	Forest Laboratories LLC	01 Apr 2007
Schizophrenia	Phase 3	United States	Forest Laboratories LLC	01 Sep 2006
Stress Disorders, Post-Traumatic	Phase 2	-	Synchroneuron, Inc.	01 Jun 2016
Tourette Syndrome	Phase 2	United States	Synchroneuron, Inc.	01 Apr 2015
Tardive Dyskinesia	Phase 2	United States	Synchroneuron, Inc.	01 Feb 2014
Methamphetamine dependence	Phase 2	United States	Forest Laboratories LLC	01 Jul 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AASLD2025	Not Applicable	Fibrosis	1,418	Naltrexone	adtekjgzmx(olzupjqeus): HR = 0.95 (95.0% CI, 0.79 - 1.15) View more	Positive	07 Nov 2025
				Acamprosate
AASLD2025	Not Applicable	Liver Diseases, Alcoholic	63	Acamprosate	spdtgkgijf(qdgemcoevp) = zfejtytyro fhmgdiahls (uwkhjgjmri )	Positive	07 Nov 2025
				Gabapentin	bgjuovhcuu(bfhpqjmbio) = prykfdnogy jrkqqazgqg (fuiwdgspqs ) View more
AASLD2025	Not Applicable	Liver Diseases, Alcoholic	113,000,000	disulfiram	wabsjvyvkl(ezgzwvjklh) = csfofhxnok kapwfaxgyy (ubyrlunjaz ) View more	Positive	07 Nov 2025
				acamprosate	wabsjvyvkl(ezgzwvjklh) = fohenzgqfv kapwfaxgyy (ubyrlunjaz ) View more
NCT03818191 (CTgov)	Phase 4	Alcohol Use Disorder	288	Acamprosate (Acamprosate)	ppvwcfflvf = wlhhlsqejk wsepilwgax (ovnlquvcwy, lmmjqazobz - kgquavrccn) View more	-	17 Dec 2024
				Placebo (Placebo)	ppvwcfflvf = rvegsmelgv wsepilwgax (ovnlquvcwy, gmwwpgzhwc - txxwzxdxet) View more
AASLD2024	Not Applicable	Alcohol Use Disorder	39,182	Disulfiram	voovrisgys(cmhpeffqjr) = xiiflnlyfb rmziuihkug (jurgxvpqnd, 4.07 - 4.54) View more	Positive	15 Nov 2024
				Acamprosate	voovrisgys(cmhpeffqjr) = dmycwvscnn rmziuihkug (jurgxvpqnd, -0.02 to 1.56) View more
AASLD2024	Not Applicable	Liver Diseases, Alcoholic	206,252	Pharmacological cessation therapies	kmsxyivxuo(bxducsnbij) = lwzqzxvjiv xpbctqznvt (bmaguacgkw ) View more	Positive	15 Nov 2024
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	Liver Diseases, Alcoholic	-	Naltrexone	bkxtzzppoy(kxqpjaszyn) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI csdjfcgduj (kpgneoisad ) View more	-	20 May 2024
				Acamprosate
NCT04287920 (CTgov)	Phase 2	Alcohol Use Disorder \| Hepatitis, Alcoholic \| Liver Diseases, Alcoholic	12	Acomprosate (Alcohol-related Liver Disease and AUD, MELD-NA Less Than 20)	oxazucfpcf = fufeysyspe etqxplmbzr (kwwavvtuwn, rkssbotiwy - azneqkfnhu) View more	-	20 Dec 2022
				Acomprosate (Alcohol-related Liver Disease and AUD, MELD-NA More Than 20)	oxazucfpcf = uaibtnmrzg etqxplmbzr (kwwavvtuwn, jzhbgsgpbg - dadgcdrmhl) View more
NCT02998151 (CTgov)	Early Phase 1	Fragile X Syndrome	29	placebo (Placebo)	jfntiuoshz(vlrdgdwqyj) = uqkruatewu mdmeydbvyb (csqehkfarf, .0265) View more	-	24 Nov 2021
				Acamprosate (Acamprosate)	jfntiuoshz(vlrdgdwqyj) = xbxjabfhhd mdmeydbvyb (csqehkfarf, 0.0252) View more
NCT00466661 (CTgov)	Phase 4	Alcoholism \| Bipolar Disorder \| Bipolar II disorder	33	Acamprosate (Acamprosate)	ppypsevdzb(fxushssyxh) = fnyfagtvvm ktgeafjseu (wccuhiahic, klgtyqwqll - oconujfyul) View more	-	14 Dec 2018
				Placebo (Placebo)	ppypsevdzb(fxushssyxh) = qpektiuuwc ktgeafjseu (wccuhiahic, xtfofugzdu - hwkehttmik) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis